Cell Impact AB (publ) Logo

Cell Impact AB (publ)

CI.ST

(1.2)
Stock Price

0,18 SEK

-34.88% ROA

-39.43% ROE

-1.29x PER

Market Cap.

145.496.722,00 SEK

9.36% DER

0% Yield

-268.73% NPM

Cell Impact AB (publ) Stock Analysis

Cell Impact AB (publ) Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Cell Impact AB (publ) Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.17x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a low debt to equity ratio (18%), which means it has a small amount of debt compared to the ownership it holds

3 Graham Number

The company's Graham number indicates that it is undervalued compared to its stock price, suggesting a potentially favorable investment opportunity.

4 ROE

Negative ROE (-37.79%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (-34.42%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (0) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

Cell Impact AB (publ) Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Cell Impact AB (publ) Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Sell
4 Stoch RSI Buy

Cell Impact AB (publ) Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Cell Impact AB (publ) Revenue
Year Revenue Growth
2008 0
2009 0 0%
2010 25.917 100%
2011 1.788.414 98.55%
2012 1.132.649 -57.9%
2013 3.321.053 65.89%
2014 3.533.395 6.01%
2015 1.858.292 -90.14%
2016 1.825.746 -1.78%
2017 1.536.241 -18.85%
2018 6.564.336 76.6%
2019 11.919.000 44.93%
2020 29.309.000 59.33%
2021 71.347.000 58.92%
2022 76.812.000 7.11%
2023 37.132.000 -106.86%
2023 47.261.000 21.43%
2024 95.132.000 50.32%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Cell Impact AB (publ) Research and Development Expenses
Year Research and Development Expenses Growth
2008 0
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 41.231 100%
2018 486.000 91.52%
2019 735.000 33.88%
2020 983.000 25.23%
2021 989.000 0.61%
2022 1.587.000 37.68%
2023 0 0%
2023 3.069.000 100%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Cell Impact AB (publ) General and Administrative Expenses
Year General and Administrative Expenses Growth
2008 4.685
2009 8.216 42.98%
2010 462.162 98.22%
2011 0 0%
2012 1.494.322 100%
2013 2.820.667 47.02%
2014 3.282.750 14.08%
2015 4.462.029 26.43%
2016 5.342.955 16.49%
2017 11.556.125 53.77%
2018 21.413.193 46.03%
2019 25.112.000 14.73%
2020 26.399.000 4.88%
2021 40.310.000 34.51%
2022 43.128.000 6.53%
2023 0 0%
2023 0 0%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Cell Impact AB (publ) EBITDA
Year EBITDA Growth
2008 -4.685
2009 -8.216 42.98%
2010 -431.818 98.1%
2011 -8.673.332 95.02%
2012 -4.827.864 -79.65%
2013 -5.709.608 15.44%
2014 -5.679.994 -0.52%
2015 -6.880.848 17.45%
2016 -7.880.037 12.68%
2017 -16.882.071 53.32%
2018 -41.205.370 59.03%
2019 -42.712.000 3.53%
2020 -36.309.000 -17.63%
2021 -67.847.000 46.48%
2022 -86.222.000 21.31%
2023 -75.944.000 -13.53%
2023 -97.659.000 22.24%
2024 -51.956.000 -87.96%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Cell Impact AB (publ) Gross Profit
Year Gross Profit Growth
2008 0
2009 0 0%
2010 53.199 100%
2011 958.033 94.45%
2012 979.208 2.16%
2013 2.137.378 54.19%
2014 2.528.623 15.47%
2015 1.459.096 -73.3%
2016 666.144 -119.04%
2017 550.662 -20.97%
2018 -6.967.446 107.9%
2019 3.136.000 322.18%
2020 19.136.000 83.61%
2021 34.877.000 45.13%
2022 36.940.000 5.58%
2023 24.076.000 -53.43%
2023 -115.178.000 120.9%
2024 -78.272.000 -47.15%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Cell Impact AB (publ) Net Profit
Year Net Profit Growth
2008 4.593
2009 -129 3660.47%
2010 -417.837 99.97%
2011 -14.926.279 97.2%
2012 -8.130.677 -83.58%
2013 -7.598.146 -7.01%
2014 -7.748.991 1.95%
2015 -7.381.995 -4.97%
2016 -8.584.261 14.01%
2017 -18.291.911 53.07%
2018 -44.571.951 58.96%
2019 -49.360.000 9.7%
2020 -45.486.000 -8.52%
2021 -79.852.000 43.04%
2022 -104.214.000 23.38%
2023 -99.568.000 -4.67%
2023 -121.402.000 17.98%
2024 -83.480.000 -45.43%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Cell Impact AB (publ) Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2008 0
2009 0 0%
2010 0 0%
2011 -2 100%
2012 -1 0%
2013 -1 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 -1 0%
2019 -1 100%
2020 0 0%
2021 0 0%
2022 0 0%
2023 -1 100%
2023 -1 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Cell Impact AB (publ) Free Cashflow
Year Free Cashflow Growth
2012 -7.823.923
2013 -8.311.806 5.87%
2014 -6.840.183 -21.51%
2015 -6.187.508 -10.55%
2016 -16.569.312 62.66%
2017 -26.909.703 38.43%
2018 -51.242.435 47.49%
2019 -53.536.000 4.28%
2020 -69.637.000 23.12%
2021 -140.387.000 50.4%
2022 -174.325.000 19.47%
2023 -41.335.000 -321.74%
2023 -152.753.000 72.94%
2024 -22.219.000 -587.49%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Cell Impact AB (publ) Operating Cashflow
Year Operating Cashflow Growth
2012 -7.801.492
2013 -7.855.360 0.69%
2014 -5.855.363 -34.16%
2015 -5.558.120 -5.35%
2016 -8.922.281 37.71%
2017 -15.840.754 43.68%
2018 -42.574.149 62.79%
2019 -41.005.000 -3.83%
2020 -47.594.000 13.84%
2021 -86.075.000 44.71%
2022 -105.931.000 18.74%
2023 -26.336.000 -302.23%
2023 -100.972.000 73.92%
2024 -11.195.000 -801.94%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Cell Impact AB (publ) Capital Expenditure
Year Capital Expenditure Growth
2012 22.431
2013 456.446 95.09%
2014 984.820 53.65%
2015 629.388 -56.47%
2016 7.647.031 91.77%
2017 11.068.949 30.91%
2018 8.668.286 -27.69%
2019 12.531.000 30.83%
2020 22.043.000 43.15%
2021 54.312.000 59.41%
2022 68.394.000 20.59%
2023 14.999.000 -355.99%
2023 51.781.000 71.03%
2024 11.024.000 -369.71%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Cell Impact AB (publ) Equity
Year Equity Growth
2008 375.440
2009 375.311 -0.03%
2010 380.000 1.23%
2011 1.937.001 80.38%
2012 1.683.106 -15.08%
2013 16.083.942 89.54%
2014 8.221.634 -95.63%
2015 2.339.639 -251.41%
2016 41.380.354 94.35%
2017 23.088.443 -79.23%
2018 19.138.182 -20.64%
2019 45.053.000 57.52%
2020 201.888.000 77.68%
2021 142.625.000 -41.55%
2022 324.346.000 56.03%
2023 240.417.000 -34.91%
2023 303.369.000 20.75%
2024 259.012.000 -17.13%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Cell Impact AB (publ) Assets
Year Assets Growth
2008 388.628
2009 380.311 -2.19%
2010 16.305.961 97.67%
2011 7.897.074 -106.48%
2012 5.338.967 -47.91%
2013 19.340.855 72.4%
2014 11.303.237 -71.11%
2015 7.670.159 -47.37%
2016 52.477.072 85.38%
2017 29.560.434 -77.52%
2018 38.079.855 22.37%
2019 58.037.000 34.39%
2020 242.875.000 76.1%
2021 238.725.000 -1.74%
2022 401.513.000 40.54%
2023 318.499.000 -26.06%
2023 381.933.000 16.61%
2024 315.013.000 -21.24%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Cell Impact AB (publ) Liabilities
Year Liabilities Growth
2008 13.188
2009 5.000 -163.76%
2010 15.925.961 99.97%
2011 5.960.073 -167.21%
2012 3.655.861 -63.03%
2013 3.256.913 -12.25%
2014 3.081.603 -5.69%
2015 5.330.520 42.19%
2016 11.096.718 51.96%
2017 6.471.991 -71.46%
2018 18.941.673 65.83%
2019 12.984.000 -45.88%
2020 40.987.000 68.32%
2021 96.100.000 57.35%
2022 77.167.000 -24.54%
2023 78.082.000 1.17%
2023 78.564.000 0.61%
2024 56.001.000 -40.29%

Cell Impact AB (publ) Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.07
Net Income per Share
-0.18
Price to Earning Ratio
-1.29x
Price To Sales Ratio
3.66x
POCF Ratio
-1.36
PFCF Ratio
-1
Price to Book Ratio
0.53
EV to Sales
4.11
EV Over EBITDA
-2.15
EV to Operating CashFlow
-1.61
EV to FreeCashFlow
-1.12
Earnings Yield
-0.77
FreeCashFlow Yield
-1
Market Cap
0,15 Bil.
Enterprise Value
0,16 Bil.
Graham Number
1.33
Graham NetNet
0.02

Income Statement Metrics

Net Income per Share
-0.18
Income Quality
0.96
ROE
-0.39
Return On Assets
-0.34
Return On Capital Employed
-0.36
Net Income per EBT
1.01
EBT Per Ebit
1.03
Ebit per Revenue
-2.59
Effective Tax Rate
-0.01

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.08
Stock Based Compensation to Revenue
0
Gross Profit Margin
-1.84
Operating Profit Margin
-2.59
Pretax Profit Margin
-2.67
Net Profit Margin
-2.69

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.17
Free CashFlow per Share
-0.25
Capex to Operating CashFlow
-0.44
Capex to Revenue
1.12
Capex to Depreciation
1.66
Return on Invested Capital
-0.37
Return on Tangible Assets
-0.35
Days Sales Outstanding
280.33
Days Payables Outstanding
8.2
Days of Inventory on Hand
142.58
Receivables Turnover
1.3
Payables Turnover
44.52
Inventory Turnover
2.56
Capex per Share
0.08

Balance Sheet

Cash per Share
0,04
Book Value per Share
0,44
Tangible Book Value per Share
0.42
Shareholders Equity per Share
0.44
Interest Debt per Share
0.05
Debt to Equity
0.09
Debt to Assets
0.08
Net Debt to EBITDA
-0.24
Current Ratio
3.45
Tangible Asset Value
0,25 Bil.
Net Current Asset Value
0,04 Bil.
Invested Capital
284110000
Working Capital
0,07 Bil.
Intangibles to Total Assets
0.03
Average Receivables
0,02 Bil.
Average Payables
0,00 Bil.
Average Inventory
54914500
Debt to Market Cap
0.17

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Cell Impact AB (publ) Dividends
Year Dividends Growth

Cell Impact AB (publ) Profile

About Cell Impact AB (publ)

Cell Impact AB (publ) manufactures and sells bipolar flow plates for hydrogen fuel cells in Sweden and internationally. The company offers plates with and precise flow patterns. It serves hydrogen fuel cells producers. The company was incorporated in 1999 and is based in Karlskoga, Sweden.

CEO
Ms. Malin Lundberg
Employee
44
Address
Källmossvägen 7A
Karlskoga, 691 52

Cell Impact AB (publ) Executives & BODs

Cell Impact AB (publ) Executives & BODs
# Name Age
1 Mr. Shigeru Nakagawa
Managing Director of Cell Impact Japan Inc.
70
2 Ms. Karina Sick Larsson
Chief Human Resource Officer
70
3 Ms. Malin Lundberg
Chief Financial Officer
70
4 Mr. Henrik Jackman
Chief Application Engineer
70
5 Mr. Marcus Nilsson
Sales & Program Manager
70
6 Mr. Anders Öberg
Chief Technology Officer
70

Cell Impact AB (publ) Competitors